Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) has announced that it has received marketing approval from the Hong Kong health authorities for Quviviq (daridorexant), an anti-insomnia drug co-developed with Idorsia Pharmaceuticals Ltd. The dual orexin receptor antagonist (DORA) will now be available in 50mg and 20mg dosages in the region, offering a new treatment option for insomnia sufferers.
Quviviq, which is already commercially available in the US, UK, Italy, Germany, Switzerland, and Canada, was acquired by Simcere Pharma through a licensing agreement with Idorsia in November 2022. This agreement granted Simcere exclusive rights to develop and commercialize the drug in Greater China. Quviviq represents a breakthrough in insomnia treatment, as it works differently from traditional sleep-inducing drugs like benzodiazepines. Instead of calming the brain, daridorexant reduces arousal drive and promotes sleep by blocking orexin receptors, without altering the patient’s sleep structure or causing residual effects the following day. Clinical studies have demonstrated that daridorexant can significantly improve sleep duration and is suitable for long-term use.- Flcube.com
